Sotrovimab:
Again one more monoclonal antibody which is approved only for mild to moderate COVID (Like Bamlanivimab and Etesivimab). Not only that “Sotrovimab and other monoclonal antibodies are associated with worse Clinical outcome when administered to hospitalised patients requiring high flow oxygen and mechanical ventilation”
Why cheers again and again?
Time for FDA/EMA to concentrate on drugs which can be used for hospitalised patients.